Clinical Trial Update: Panobinostat in Combination With Carfilzomib and Dexamethasone in Relapsed or Relapsed and Refractory Multiple Myeloma [Phase 2]

View source ↗

Summary

A Phase 2 trial evaluating panobinostat in combination with carfilzomib and dexamethasone for relapsed and/or refractory multiple myeloma has been withdrawn.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Multiple Myeloma

Drugs mentioned

• DEXAMETHASONE (Dexamethasone)
• Farydak (panobinostat)
• Kyprolis (carfilzomib)

Snippet

Sponsor: Novartis Pharmaceuticals | Conditions: Multiple Myeloma | Phase 2 | Status: WITHDRAWN